Biomarker Reference · ASMA
Anti-Smooth Muscle Antibodies (ASMA) is a clinical biomarker used in gastrointestinal assessment. Anti-smooth muscle antibodies are directed against cytoskeletal filamentous actin (F-actin) and other smooth-muscle components. It is measured in 1 laboratory test on BiomarkersLabs.com.
Anti-smooth muscle antibodies are directed against cytoskeletal filamentous actin (F-actin) and other smooth-muscle components. They arise in the setting of immune-mediated hepatocyte injury and are a characteristic, though not entirely specific, feature of autoimmune hepatitis. The F-actin subtype is more specific for AIH than antibodies to other smooth-muscle antigens.
ASMA is present in 60–80 per cent of patients with type 1 autoimmune hepatitis, often alongside antinuclear antibodies. A high titre (≥1:80) in the presence of hepatocellular injury and elevated immunoglobulin G strongly supports the diagnosis, particularly when F-actin specificity is confirmed. ASMA can also be detected at low titre in viral hepatitis, primary biliary cholangitis, and other chronic liver diseases, so it should be interpreted as part of the full autoimmune liver serology and clinical picture.
Reference ranges vary by laboratory and assay platform. Interpret in context of the issuing laboratory's stated range.
1 test on BiomarkersLabs.com include this biomarker.
Available exclusively to verified licensed healthcare practitioners. CLIA-certified laboratory results delivered to your secure portal.
Create Free Account